Eloxx Pharmaceuticals, Inc.
ELOX, ELOXD · Biological Products, (No Diagnostic Substances) · 7.6M shares · +14%/yr ↑ shares · EDGAR filings ↗
Net buyback after stock comp: -$3M (gross -$1M, SBC $2M)
Grade
F40Going-concern clinical micro-cap, delisted to OTC with delinquent filings and near-zero cash, lead program only entering Phase 2b.
Strengths
- Orphan drug designations and clean tolerability across 145 dosed subjects
- Almirall partnership (ZKN-013) provides up to ~$470M in potential milestones plus non-dilutive upfront
Risks
- Going concern doubt; cash $4.8M (9.7th pct), current ratio 0.31 (8.7th pct) — near cash-out
- Nasdaq-delisted, OTC Expert Market, delinquent SEC filings — severe governance/access red flags
- Only trial_result is an uninterpretable n=3 open-label safety read; no efficacy signal
Notable findings
- Going concern• Our recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern
- Exec changeRecent 8-K item 5.02 8-K ↗
- Weak liquidityCurrent ratio 0.31 (<1)
- Chronic dilutionShare count +14%/yr over 3y (dilution)
- Revenue declineRevenue -100.0% YoY
Key metrics
Return on equity
50.3%
Return on assets
-113.8%
Debt / equity
0.0×
Current ratio
0.3×
Tangible book value
-$12M
Cash & investments
$5M
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-10 | Domicilium Real Estate Fund III LP | Other | 238K | — |
| 2026-06-10 | Domicilium Real Estate Fund III LP | Other | 362K | — |
| 2026-05-27 | Domicilium Real Estate Fund III LP | Other | 114K | — |
| 2026-05-27 | Coastlands Capital LP | Other | 1.2M | — |
| 2026-02-28 | Aggarwal Sumit | Option exercise | 261K | $0.15 |
| 2026-01-24 | Aggarwal Sumit | Option exercise | 15K | — |
| 2026-01-24 | Rubin Steven D | Option exercise | 1.9K | — |
| 2026-01-24 | Walts Alan Edmund | Option exercise | 1.9K | — |
| 2025-09-19 | Aggarwal Sumit | Grant | 1.0M | — |
| 2025-08-14 | Aggarwal Sumit | Option exercise | 197K | $0.00 |
| 2025-01-24 | Walts Alan Edmund | Option exercise | 3.8K | — |
| 2025-01-24 | Aggarwal Sumit | Option exercise | 30K | — |
| 2025-01-24 | Rubin Steven D | Option exercise | 3.8K | — |
| 2025-01-24 | Androski Lindsay | Option exercise | 3.8K | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07523581 ↗ | EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive | PHASE2 | Not Yet Recruiting | 2027-06-30 |
| NCT05448755 ↗ | A Study of ELX-02 in Patients With Alport Syndrome Alport Syndrome | PHASE2 | Completed | 2023-09-11 |
| NCT04135495 ↗ | A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele Cystic Fibrosis | PHASE2 | Completed | 2022-10-03 |
| NCT04126473 ↗ | A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele Cystic Fibrosis | PHASE2 | Completed | 2022-04-06 |
| NCT04069260 ↗ | A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis Genetic Disease, Nonsense Mutation | PHASE2 | Terminated | 2019-12-17 |
| NCT03776539 ↗ | A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02 Impaired Renal Function | PHASE1 | Completed | 2019-07-30 |
| NCT03309605 ↗ | Phase 1 Study of ELX-02 in Healthy Adult Subjects Genetic Disease, Nonsense Mutation | PHASE1 | Completed | 2019-06-17 |
| NCT03292302 ↗ | Phase 1 Study of ELX-02 in Healthy Adults Genetic Disease, Nonsense Mutation | PHASE1 | Completed | 2017-12-15 |
| NCT02807961 ↗ | Safety, Tolerability, Pharmacokinetics of ELX-02 in Healthy Adult Volunteers Genetic Diseases, Nonsense Mutations | PHASE1 | Terminated | 2017-02-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Supply chain
Customers (1)
- Almirall, S.A.
Suppliers (0)
Named in the 10-K; linked when we track them.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-01 | 3.023.03Exec/director change5.03Exhibits | filing ↗ |
| 2026-05-01 | Shareholder vote | filing ↗ |
| 2025-08-12 | Exec/director changeExhibits | filing ↗ |
| 2024-10-17 | Exec/director changeExhibits | filing ↗ |
| 2024-07-16 | Material agreementDebt obligation | filing ↗ |
| 2024-03-29 | Exec/director change | filing ↗ |
| 2024-03-14 | Material agreement | filing ↗ |
| 2024-01-09 | Material agreement3.02 | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-01 | 2026-05-27 | 0001193125-26-249692 ↗ |
| 10-Q | 2026-05-05 | 2026-03-31 | 0001193125-26-204722 ↗ |
| 8-K | 2026-05-01 | 2026-04-28 | 0001193125-26-201408 ↗ |
| 10-K | 2026-03-17 | 2025-12-31 | 0001193125-26-108687 ↗ |
| 8-K | 2025-08-12 | 2025-08-06 | 0001104659-25-076933 ↗ |
| 8-K | 2024-10-17 | 2024-10-16 | 0001104659-24-109521 ↗ |
| 8-K | 2024-07-16 | 2024-07-10 | 0001104659-24-080251 ↗ |
| 8-K | 2024-03-29 | 2024-03-25 | 0001104659-24-041148 ↗ |
| 8-K | 2024-03-14 | 2024-03-11 | 0001104659-24-034529 ↗ |
| 8-K | 2024-01-09 | 2024-01-09 | 0001104659-24-002631 ↗ |
| 8-K | 2023-12-28 | 2023-12-27 | 0001104659-23-130052 ↗ |
| 8-K | 2023-12-15 | 2023-12-15 | 0001104659-23-126400 ↗ |